PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease

Neurology

Volumn 52, Issue 6, 1999, Pages 1221-1226

  Ilgin, N ^a   Zubieta, J ^b   Reich, S G ^a   Dannals, R F ^a   Ravert, H T ^a   Frost James J , J J ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; HUMAN; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN;

EID: 0032944084     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.6.1221     Document Type: Article

References (38)

1. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(suppl):S125-127.
2. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994;57:278-284.
3. Tolosa E, Valldeoriola F, Marti MJ. Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy. J Neural Transm 1994;42(suppl):229-246.
4. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. J Neurol Sci 1991;18: 275-278.
5. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
6. 18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993;13:43-56.
7. 18F]fluorodopa probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res 1990;27:487-493.
8. 18F]fluoro-dopa in human positron emission tomographic studies. J Cereb Blood Flow Metab 1991;11:898-913.
9. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
10. 11C]-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
11. 3H]WIN 35,428 to central dopamine transporters. Synapse 1996;23:61-69.
12. 11C]-WIN 35,428. J Label Compounds Radiopharmacol 1993;33:147-152.
13. Johnson KA, Sperling RA, Holman BL, Nagel JS, Growdon JH. Cerebral perfusion in progressive supranuclear palsy. J Nucl Med 1992;33:704-709.
14. Leenders KL, Frajkowiak RSJ, Lees AJ. Steele-Richardson-Olszewski syndrome: brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 1988;111:615-630.
15. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-860.
16. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
17. Leenders KL. Parkinson's disease and PET tracer studies. J Neural Transm Suppl 1988;27:219-225.
18. Bhatt MH, Snow BJ, Martin WR, Pate BD, Ruth TJ, Calne DB. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol 1991;29:673-677.
19. Gibb WR. Neuropathology of Parkinson's disease and related syndromes. Neurol Clin 1992;10:361-376.
20. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
21. Kish SJ, Shannak K, Rajput A, Deck JHN, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992;58:642-648.
22. Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989;26:766-770.
23. Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm 1994;42(suppl): 229-246.
24. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and limbic' functions. Prog Brain Res 1990; 85:119-146.
25. Rinne JO, Rummukainen J, Paljarvi L, et al. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50.
26. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884.
27. Volkow ND, Ding YS, Fowler JS, et al. Dopamine transporters decrease with age. J Nucl Med 1996;37:554-559.
28. Baron JC, Maziere B, Loc'h C, et al. Loss of striatal [76Br] bromospiperone binding sites demonstrated by positron emission tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 1986;6:131-136.
29. 18F]fluoroethylspiperone: findings on disorders related to the dopaminergic system. J Neural Transm Gen Sect 1990;81:195-213.
30. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-192.
31. Van Royen E, Verhoeff NF, Speelman JD, Wolters EC, Kuiper MA, Janssen AG. Multiple system atrophy and progressive supranuclear palsy: diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 1993;50:513-516.
32. Soucy JP, Mrini A, Lafaille F. Assessment of WIN 35428 and GBR 12935 as quantitative markers of dopamine (DA) innervation density in brain. J Nucl Med 1995;36:118. Abstract.
33. Kish SJ, Levey AI, Hornykiewicz O, et al. Striatal protein concentration of the dopamine transporter is markedly reduced in idiopathic Parkinson's disease. Abstracts for the Society of the Neuroscience Meeting. Soc Neurosci Abstr 1995; 21:1251.
34. 11C]tetrabenazine and positron emission tomography. J Neurochem 1993;60:2315-2318.
35. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718-726.
36. Graybiel AM, Hirsch EC, Agid Y. The nigrostriatal system in Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Advances in neurology, vol 53, Parkinson's disease: anatomy, pathology and therapy. New York: Raven Press, 1990:17-29.
37. Calne DB, Zigmond MJ. Compensatory mechanisms in degenerative neurologic diseases: insights from parkinsonism. Arch Neurol 1991;48:361-363.
38. Cotman CW, Nieto-Sanpedro M, Harris EW. Synapse replacement in the nervous system of adult vertebrates. Physiol Rev 1981;61:684-784.